Summary To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC), we 10.5 months (range 0.5-70 +) and 7 months (range 0.5-24) in those with extensive disease. Improvement of symptoms occurred in 79% of patients with shortness of breath, 80% with cough, 81% with haemoptysis and 68% with pain. In 19 patients an increase in body weight was noted. Major (WHO grade 3/4) toxicities were neutropenia in 13 (18.5%) patients, alopecia in 33 (47.1%) patients, mucositis in 15 (21.4%) patients, anorexia in eight patients (11.4%), nausea and vomiting in six patients (8.5%) and diarrhoea in 4 (5.7%) patients. In conclusion, EE is an active and well-tolerated outpatient regimen in the treatment of SCLC. The survival data in this unselected group of patients were disappointing and the possible explanations for this are discussed.
The standard therapy for patients with small-cell lung cancer (SCLC) is combination chemotherapy (Hansen, 1992) . It significantly prolongs survival and can even cure a small number of patients with limited disease. However, the majority of patients, including those with limited disease, develop distant metastases and die as a result of their disease (Albain et al, 1990) .
No standard cytotoxic regimen exists for the treatment of SCLC (Hansen, 1992) . Various combinations have been tried, the most long-standing being cyclophosphamide, doxorubicin and vincristine (CAV). More recently, cisplatin with etoposide (PE) has become a commonly used regimen , with preliminary results suggesting an increased response rate in limited disease when used with irradiation (Johnson et al, 1994) . The addition of ifosfamide resulted in the VIP regimen (etoposide, ifosfamide and cisplatin), for which a survival advantage has been claimed in extensive disease . More recently, carboplatin has replaced cisplatin, with a similar response rate and survival advantage being observed in patients with extensive disease (Wolf et al, 1995) . However, both these regimens require inpatient administration of up to 4 days, considerably adding to the inconvenience to the patient and to the cost of treatment.
Etoposide is a phase-specific drug, acting as a topoisomerase inhibitor during late S phase or early G2 phase of the cell cycle. It has been used as a single agent for first-line treatment in SCLC, with a reported overall response rate in untreated patients of 35-85% (Pedersen and Hansen, 1983; Slevin et al, 1989) .
Prolonged administration was associated with significantly higher complete and overall response rates, as well as improvement in median survival time (Abratt et al, 1987; Slevin et al, 1989) .
Epirubicin (4-epidoxorubicin), the stereoisomer of doxorubicin, with less severe cardiotoxic effects than the parent compound, has a recommended maximum cumulative dose twice that of doxorubicin (Plosker and Faulds, 1993) . Three trials have demonstrated the activity of epirubicin in SCLC (Blackstein et al, 1990; Eckhardt et al, 1990; Macchiarini et al, 1990a) . In the first two, previously untreated patients with extensive disease were treated every 3 to 4 weeks at a dose of 100 mg m-2 and 120 mg m-2, and overall response rates of 50% and 48% were reported respectively. In the third trial patients with limited disease were also entered and an overall response rate of 33% was seen (Macchiarini et al, 1990a) .
In the present study, we aimed to evaluate the activity of the combination of epirubicin and oral etoposide with respect to its toxicity profile, improvement in symptoms and effect on survival. In addition, this particular regimen could be given in an outpatient setting.
PATIENTS AND METHODS
From December 1989 to May 1995, 70 consecutive previously untreated patients with a cytologically/histologically confirmed diagnosis of SCLC were treated according to a standard protocol. Patients received epirubicin 80 mg m-2 i.v. on day 1 and etoposide 200 mg orally o.d. on days 1-4 at 3-weekly intervals. Epirubicin was administered by intravenous infusion over 30 min and etoposide as 50 mg capsules. This combination was given provided there was adequate haematological (white blood cell count of 2 4000 ul-1, platelet count of 2 100 000 g1-1), renal (serum creatinine < 1.5 mg dl-') and hepatic (total serum bilirubin < 2 mg dl-') function. Those patients considered unfit for this treatment were given single-agent oral etoposide. Patients with a recent myocardial infarction (within 3 months of SCLC diagnosis), congestive heart failure, significant arrhythmia or uncontrolled infectious disease were also excluded.
Drug doses were reduced to 75% in the event of neutropenic sepsis or thrombocytopenia requiring transfusion. The treatment was postponed for 1 or 2 weeks to allow recovery of haematological function (white blood cell count 2 4000 p1-1 and platelet count 2 100 000 p1-').
The 
EVALUATION OF RESPONSE AND TOXICITY Response
The efficacy of treatment was evaluated in terms of response, duration of response and survival. Response criteria were those defined by the WHO. Patients were assessable for response provided they completed one or more courses of treatment. Time to progression was calculated as the time from start of cytotoxic therapy until definite progression or death. Survival was measured from the first day of treatment to the date of death (of any cause) or last follow-up.
Toxicity
The WHO criteria were used to report toxicity. All patients who received at least one dose were considered evaluable for toxicity. The toxicity is reported as the worst experienced for all cycles per patient. Symptomatic improvement All patients were asked to assess the severity of their symptoms, e.g. cough, haemoptysis, dyspnoea and chest pain, on a five-point scale (0-4) on the first day of treatment for each cycle. Any reduction in severity by 2 1 on this scale was taken as evidence of symptomatic improvement.
Statistical analysis
Survival and duration of response curves were estimated by the Kaplan-Meier method (Kaplan and Meier, 1958) . In the survival analysis, all causes of death were considered. All median values are followed by range, and frequencies expressed in percentages followed by 95% confidence intervals (CIs).
RESULTS

Response to treatment and survival
Patient characteristics are shown in Radiotherapy to the chest was also given to four patients as palliation and to four at the time of relapse. Cranial irradiation was given for palliation of cerebral metastases in 13 patients.
DISCUSSION
Although SCLC is highly sensitive to both chemotherapy and radiotherapy, the majority of patients are destined to die of progressive disease. Many different chemotherapy regimens have been evaluated but no major advances have resulted from autologous bone marrow transplantation, the use of granulocyte colonystimulating factor (G-CSF) to escalate the doses or to increase the dose frequency, or by novel combinations of existing drugs (Klastersky, 1995) . Until such time as new drugs and drug combinations have been identified that enhance both response rates and survival durations, treatment should be with a regimen that combines efficacy with patient acceptability, low toxicity and cost.
The combination of epirubicin and etoposide has been tested in several phase II trials but always in addition to other drugs, such as cyclophosphamide (Macchiarini et al, 1990b) , cisplatin (Rosell et al, 1992) , ifosfamide (Sculier et al, 1995) or in four drug regimens (Bamberga et al, 1992) .
Variable doses of anthracycline, either doxorubicin (45 mg m-2) or epirubicin (60 mg m-2 or 90 mg m-2), given on day 1 with ifosfamide (1.5 g m-2) and etoposide (80 mg m-2) day 1-3, resulted in response rates varying from 73% to 83% (Sculier et al, 1995) . The overall median survival was 42 weeks, which is very similar to our own results. Higher doses of epirubicin (100-120 mg m-2) given on day 1 with cisplatin (70 mg m-2) and etoposide (60-80 mg m-2) for days 1-5 had a higher response rate at 81% and median survival of 13 months (Rosell et al, 1992) . However, this was at the expense of increased toxicity with 53% neutropenic fever and 40% stomatitis compared with 15% grade 3 and 4 infection and 3% stomatitis in the ifosfamide-containing combination. Our own toxicity data showed the two-drug regimen to have a 15.7% rate of neutropenic sepsis and 21.4% for stomatitis. The planned epirubicin dose intensity up to 120 mg m-2, which was approximately 30% higher than that used by both Sculier and ourselves, may well explain both the increased activity seen with this regimen as well as the marked toxicity.
Unfortunately, even though both epirubicin and etoposide are active single agents for SCLC, our response and survival data may be compromised as many of our patients had poor prognostic features such as hyponatraemia (11 patients), elevated LDH (29 patients) and syndrome of inappropriate antidiuretic hormone (three patients). Poor performance status (PS 3) patients were also included and not all the patients with limited disease received thoracic irradiation, which has subsequently been demonstrated to add to the benefit of chemotherapy. The value of thoracic irradiation in patients with limited disease was uncertain at the time this protocol was initiated.
The addition of a third drug or combining etoposide with a platinum compound might have been beneficial. The combination of carboplatin with oral etoposide gave an overall response rate of 67%, with a complete response of 21% in 106 patients (Pfeiffer et al, 1995) . These results are similar to our own (overall response rate 66.6% and complete response 24.5%). Their response rate in patients with limited disease was higher (89% with CR 41%) than ours (77.4% with CR 32%) and the median survival at 15 months was comparable to that obtained in trials in which both the carboplatin and etoposide were administered intravenously.
Myelosuppression was the main toxicity, with grade 3 or 4 leucopenia observed in 20% of patients and thrombocytopenia in 16% of patients. In a further study, a combination of oral etoposide 100 mg m-2 for 7 days and carboplatin 150 mg m-2 i.v. on day 1 was given to 47 elderly (> 45 years) or medically unfit patients with SCLC (Evans et al, 1995) . Of the 38 patients evaluable for response, 71% responded with a complete response in 29% of patients. The median survival was 46 weeks and the treatment was generally well tolerated, with the major toxicity being neutropenia. Both these studies and our study show that oral etoposide can be incorporated in regimens for SCLC administered on an outpatient basis that are effective and well tolerated.
The relatively poor results in terms of survival in our study would imply that our regimen has less activity than a platinum-etoposide combination. It is not clear why this should be. It is perhaps accentuated by reporting the results of unselected patients compared with highly selected patients in phase JI/T studies. Interestingly, a very short median survival of only 20 weeks was seen in an MRC study comparing ECMV (etoposide, cyclophosphamide, methotrexate and vincristine) with EV (etoposide and vincristine) (Bleehen et al, 1996) . This was in part thought to be related to patients of poor performance status as well as a high proportion (17%) of early deaths, which may have been due to undiagnosed sepsis. Our own early death rate was lower at 10%, but was still a significant proportion. In addition, the efficacy of oral etoposide as a single agent has recently been questioned (Thatcher et al, 1996; MRC Lung Cancer Working Party, 1996) . A multicentre randomized trial of oral etoposide compared with standard intravenous multidrug chemotherapy was stopped owing to poor response rates of 45% vs 51% respectively.
In view of the poor duration of survival we reported with oral etoposide and epirubicin, we have decided to consider a platinumbased regimen in future.
